Which class of drugs does Daprodustat belong to and its classification introduction

Daprodustat is classified as a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) in the drug classification. The main mechanism of action of this class of drugs is to indirectly stabilize HIF transcription factors by inhibiting the activity of prolyl hydroxylase, thereby enhancing the body's ability to adapt to hypoxic conditions and promoting the secretion of endogenous erythropoietin (EPO). Compared with traditional recombinant EPO injection preparations, HIF-PHI drugs are closer to physiological regulation and have certain advantages in safety and long-term compliance.

From the perspective of pharmacological classification, daprostat belongs to the category of anti-anemia drugs and is especially suitable for the treatment of patients with chronic kidney disease combined with anemia. For a long time, the treatment of anemia related to chronic kidney disease has mostly relied on exogenous EPO preparations. Although these drugs can effectively increase hemoglobin levels, they also have adverse reactions and the inconvenience of frequent injections in clinical application. Daprostat, as a small molecule oral preparation, can stably improve anemia symptoms orally, which makes it of great innovative significance in drug classification and clinical application.

In the global drug classification system, daprostat is usually included in the small molecule oral hypoxia-inducible factor stabilizer, which belongs to the same category as Roxadustat and Vadadustat. It is worth noting that although they all belong to HIF-PHI, different drugs have differences in molecular structure, metabolic pathways and pharmacokinetic characteristics, which also leads to slightly different efficacy and tolerability in different populations.

In recent years, research on theHIF pathway has continued to in-depth. As one of the representative drugs, daprostat is regarded as an important breakthrough to improve the treatment of anemia after recombinant EPO. This type of drug can not only stimulate EPO secretion, but may also improve iron metabolism-related indicators and reduce functional iron deficiency in an inflammatory environment. Therefore, from a classification perspective, it is not only a hematopoiesis promoter in the traditional sense, but also has the potential advantage of multi-target regulation.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat